Cost-effectiveness of high dose versus adjuvanted trivalent influenza vaccines in England and Wales

References

• Mertz D, Kim TH, Johnstone J, et al. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ. 2013;347:f5061.
   PubMed Web of Science ®Google Scholar
• Agor JK, Özaltın OY. Models for predicting the evolution of influenza to inform vaccine strain selection. Hum Vaccin Immunother. 2018;14(3):678–683.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Influenza (seasonal) fact sheet [Internet]. Geneva (Switzerland): WHO; 2016 [cited 2019 Sep 25]. Available from: https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)
   Google Scholar
• Osterholm MT, Kelley NS, Sommer A, et al. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):36–44.
   PubMed Web of Science ®Google Scholar
• Sasaki S, Sullivan M, Narvaez CF, et al. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Invest. 2011;121(8):3109–3119.
   PubMed Web of Science ®Google Scholar
• Lee JK, Lam GK, Shin T, et al. Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis. Expert Rev Vaccines. 2018;17(5):435–443.
   PubMed Web of Science ®Google Scholar
• Robertson CA, DiazGranados CA, Decker MD, et al. Fluzone® high-dose influenza vaccine. Expert Rev Vaccines. 2016;15(12):1495–1505.
   PubMed Web of Science ®Google Scholar
• DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371(7):635–645.
   PubMed Web of Science ®Google Scholar
• DiazGranados CA, Dunning AJ, Jordanov E, et al. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season. Vaccine. 2013;31(6):861–866.
   PubMed Web of Science ®Google Scholar
• Gravenstein S, Davidson HE, Han LF, et al. Feasibility of a cluster-randomized influenza vaccination trial in U.S. nursing homes: lessons learned. Hum Vaccin Immunother. 2018;14(3):736–743.
   PubMed Web of Science ®Google Scholar
• Gravenstein S, Davidson HE, Taljaard M, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial. Lancet Respir Med. 2017;5(9):738–746.
   PubMed Web of Science ®Google Scholar
• Izurieta HS, Chillarige Y, Kelman J, et al. Relative effectiveness of influenza vaccines among the United States elderly, 2018-2019. J Infect Dis. 2020;222(2):278–287.
   PubMed Web of Science ®Google Scholar
• Izurieta HS, Thadani N, Shay DK, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using medicare data: a retrospective cohort analysis. Lancet Infect Dis. 2015;15(3):293–300.
   PubMed Web of Science ®Google Scholar
• Richardson DM, Medvedeva EL, Roberts CB, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccination in community-dwelling veterans. Clin Infect Dis. 2015;61(2):171–176.
   PubMed Web of Science ®Google Scholar
• Robison SG, Thomas AR. Assessing the effectiveness of high-dose influenza vaccine in preventing hospitalization among seniors, and observations on the limitations of effectiveness study design. Vaccine. 2018;36(45):6683–6687.
   PubMed Web of Science ®Google Scholar
• Shay D, Chillarige Y, Kelman J, et al. Comparative effectiveness of High-Dose versus Standard-Dose influenza vaccines among US medicare beneficiaries in preventing postinfluenza deaths during 2012-2013 and 2013-2014. J Infect Dis. 2017;215(4):510–517.
   PubMed Web of Science ®Google Scholar
• Young-Xu Y, Snider JT, van Aalst R, et al. Analysis of relative effectiveness of high-dose versus standard-dose influenza vaccines using an instrumental variable method. Vaccine. 2019;37(11):1484–1490.
   PubMed Web of Science ®Google Scholar
• Young-Xu Y, Van Aalst R, Mahmud SM, et al. Relative vaccine effectiveness of high-dose versus Standard-Dose influenza vaccines among veterans health administration patients. J Infect Dis. 2018;217(11):1718–1727.
   PubMed Web of Science ®Google Scholar
• Lee JK, Lam GK, Shin T, et al. Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: an updated systematic review and meta-analysis. Vaccine. 2021;39:A24–A35.
   PubMed Web of Science ®Google Scholar
• Joint Committee on Vaccination and Immunisation. JCVI advice on influenza vaccines for 2021-2022 [Internet]. London (UK): JCVI; 2020 [cited 2021 Jul 19]. Available from: https://app.box.com/s/t5ockz9bb6xw6t2mrrzb144njplimfo0/file/737845224649)
   Google Scholar
• Haq K, McElhaney JE. Immunosenescence: influenza vaccination and the elderly. Curr Opin Immunol. 2014;29:38–42.
   PubMed Web of Science ®Google Scholar
• Domnich A, Arata L, Amicizia D, et al. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: a systematic review and meta-analysis. Vaccine. 2017;35(4):513–520.
   PubMed Web of Science ®Google Scholar
• Pebody RG, Whitaker H, Ellis J, et al. End of season influenza vaccine effectiveness in primary care in adults and children in the United Kingdom in 2018/19. Vaccine. 2020;38(3):489–497.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Systematic review of the efficacy, effectiveness and safety of newer and enhanced seasonal influenza vaccines for the prevention of laboratory confirmed influenza in individuals aged 18 years and over. Stockholm (Sweden): ECDC; 2020.
   Google Scholar
• Beran J, Reynales H, Poder A, et al. Prevention of influenza during mismatched seasons in older adults with an MF59-adjuvanted quadrivalent influenza vaccine: a randomised, controlled, multicentre, phase 3 efficacy study. The Lancet Infect Dis. 2021;21(7):1027–1037.
   PubMed Web of Science ®Google Scholar
• National Advisory Committee on Immunization. Literature review update on the efficacy and effectiveness of High-Dose (fluzone® High-Dose) and MF59-adjuvanted (fluad®) trivalent inactivated influenza vaccines in adults 65 years of age and older. Ottawa (Canada): PHAC; 2018.
   Google Scholar
• van Aalst R, Gravenstein S, Mor V, et al. Comparative effectiveness of high dose versus adjuvanted influenza vaccine: a retrospective cohort study. Vaccine. 2020;38(2):372–379.
   PubMed Web of Science ®Google Scholar
• Trucchi C, Paganino C, Orsi A, et al. Hospital and economic burden of influenza-like illness and lower respiratory tract infection in adults ≥50 years-old. BMC Health Serv Res. 2019;19(1):585.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal [Internet]. London (UK): NICE; 2013 [cited 2021 March 9]. Available from: https://www.nice.org.uk/process/pmg9/chapter/the-reference-case
   Google Scholar
• Public Health England. Annual flu reports [Internet]. London (UK): PHE; 2018 [cited 2019 Nov 19]. Available from: https://www.gov.uk/government/statistics/annual-flu-reports
   Google Scholar
• World Health Organization. WHO global epidemiological surveillance standards for influenza. Geneva (Switzerland); WHO.
   Google Scholar
• Millett ER, Quint JK, Smeeth L, et al. Incidence of community-acquired lower respiratory tract infections and pneumonia among older adults in the United Kingdom: a population-based study. PLoS One. 2013;8(9):e75131.
   PubMed Web of Science ®Google Scholar
• Fleming DM, Andrews NJ, Ellis J, et al. Estimating influenza vaccine effectiveness using routinely collected laboratory data. J Epidemiol Community Health. 2010;64(12):1062–1067.
   PubMed Web of Science ®Google Scholar
• Baguelin M, Camacho A, Flasche S, et al. Extending the elderly-and risk-group programme of vaccination against seasonal influenza in England and Wales: a cost-effectiveness study. BMC Med. 2015;13(1):236.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Systematic review of the efficacy, effectiveness and safety of newer and enhanced seasonal influenza vaccines 2020 [Internet]. Solna (Sweden): ECDC; 2020 [cited 9 Mar 2021]. Available from: https://www.ecdc.europa.eu/en/publications-data/seasonal-influenza-systematic-review-efficacy-vaccines
   Google Scholar
• Michaelis K, Scholz S, Buda S, et al. Beschluss und wissenschaftliche begründung der ständigen impfkommission (STIKO) für die aktualisierung der Influenza-Impfempfehlung für personen im alter von ≥ 60 jahren. 2020;(1):3–25. Available from: https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/Ausgaben/01_21.pdf?__blob=publicationFile
   Google Scholar
• Puig-Barberà J, Natividad-Sancho A, Calabuig-Pérez J, et al. MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system. Vaccine. 2013;31(37):3995–4002.
   PubMed Web of Science ®Google Scholar
• Mannino S, Villa M, Apolone G, et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in Northern Italy. Am J Epidemiol. 2012;176(6):527–533.
   PubMed Web of Science ®Google Scholar
• Thorrington D, van Leeuwen E, Ramsay M, et al. Assessing optimal use of the standard dose adjuvanted trivalent seasonal influenza vaccine in the elderly. Vaccine. 2019;37(15):2051–2056.
   PubMed Web of Science ®Google Scholar
• Pitman R, Melegaro A, Gelb D, et al. Assessing the burden of influenza and other respiratory infections in England and Wales. J Infect. 2007;54(6):530–538.
   PubMed Web of Science ®Google Scholar
• Matias G, Taylor RJ, Haguinet F, et al. Modelling estimates of age-specific influenza-related hospitalisation and mortality in the United Kingdom. BMC Public Health. 2016;16(1):481.
   PubMed Web of Science ®Google Scholar
• Office for National Statistics. National life tables Great Britain (2014-2016) [Internet]. Newport (UK): Office for National Statistics; 2017 [cited 2019 Nov 19]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesunitedkingdomreferencetables
   Google Scholar
• Szende A, Janssen B, Cabases J. Self-reported population health: an international perspective based on EQ-5D. Dordrecht (The Netherlands): Springer; 2014.
   Google Scholar
• Turner DA, Wailoo AJ, Nicholson KG, et al. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess. 2003;7(35):1–170.
   Google Scholar
• Pitman R, Nagy L, Sculpher MJV. Cost-effectiveness of childhood influenza vaccination in England and Wales: results from a dynamic transmission model. Vaccine. 2013;31(6):927–942.
   PubMed Web of Science ®Google Scholar
• Curtis LA, Burns A. Unit costs of health and social care 2018. Canterbury (UK): Personal Social Services Research Unit (PSSRU); 2018.
   Google Scholar
• NHS UK. NHS reference costs 2016/17 [Internet]. London (UK): NHS; 2018 [cited 2019 Nov 19]. Available from: https://improvement.nhs.uk/resources/reference-costs/
   Google Scholar
• Appleby J. Nuffield winter insight briefing 1: winter beds pressures. J Nuffield Trust. 2016;:2017–2001. Available from: https://www.nuffieldtrust.org.uk/files/2017-01/winter-beds-pressures-final.pdf
   Google Scholar
• Green HK, Andrews N, Fleming D, et al. Mortality attributable to influenza in England and Wales prior to, during and after the 2009 pandemic. PLoS One. 2013;8(12):e79360.
   PubMed Web of Science ®Google Scholar
• Moss JW, Davidson C, Mattock R, et al. Quantifying the direct secondary health care cost of seasonal influenza in England. BMC Public Health. 2020;20(1):1–8.
   PubMed Web of Science ®Google Scholar
• Essink B, Fierro C, Rosen J, et al. Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults. Vaccine. 2020;38(2):242–250.
   PubMed Web of Science ®Google Scholar
• Chang L-J, Meng Y, Janosczyk H, et al. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: a phase 3 randomized clinical trial. Vaccine. 2019;37(39):5825–5834.
   PubMed Web of Science ®Google Scholar
• Schmader KE, Liu CK, Harrington T, et al. Safety, reactogenicity, and Health-Related quality of life after trivalent adjuvanted vs trivalent High-Dose inactivated influenza vaccines in older adults: a randomized clinical trial. JAMA Netw Open. 2021;4(1):e2031266.
   PubMed Web of Science ®Google Scholar
• Laurie KL, Rockman S. Which influenza viruses will emerge following the SARS‐CoV‐2 pandemic? Influenza Other Respi Viruses. 2021;15(5):573–576.
   PubMed Web of Science ®Google Scholar
• Office for National Statistics (UK). Population estimates for UK, England and Wales, Scotland and Northern Ireland (mid 2016) [Internet]. Newport (UK): Office for National Statistics; 2017 [cited 2019 Nov 19]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/populationestimatesforukenglandandwalesscotlandandnorthernireland
   Google Scholar
• Public Health England. Influenza: the green book, chapter 19 [Internet]. London (UK): PHE; 2015 [cited 2019 Nov 19]. Available from: https://www.gov.uk/government/publications/influenza-the-green-book-chapter-19.
   Google Scholar
• NHS UK. HES Database - hospital admitted patient care activity, 2016-17 [Internet]. London (UK): NHS; 2017 [cited 2019 Nov 19]. Available from: https://digital.nhs.uk/data-and-information/publications/statistical/hospital-admitted-patient-care-activity/2016-17
   Google Scholar